Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
28.8M
-
Shares change
-
-84.9K
-
Total reported value, excl. options
-
$128M
-
Value change
-
-$6.93M
-
Put/Call ratio
-
0.05
-
Number of buys
-
54
-
Number of sells
-
-54
-
Price
-
$4.43
Significant Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) as of Q1 2025
130 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.8M shares
of 45.1M outstanding shares and own 63.87% of the company stock.
Largest 10 shareholders include Paradigm Biocapital Advisors LP (4.24M shares), ACORN CAPITAL ADVISORS, LLC (3.24M shares), BlackRock, Inc. (2.9M shares), Caligan Partners LP (2.34M shares), Sofinnova Investments, Inc. (2.19M shares), VANGUARD GROUP INC (1.95M shares), Polar Capital Holdings Plc (1.83M shares), GEODE CAPITAL MANAGEMENT, LLC (850K shares), STATE STREET CORP (789K shares), and BOOTHBAY FUND MANAGEMENT, LLC (694K shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.